-+ 0.00%
-+ 0.00%
-+ 0.00%

Kelun-Biotech partner Windward Bio starts Phase 3 POLARIS-1 asthma trial of SKB378/WIN378

PUBT·09/08/2026 12:05:31
Listen to the news
Kelun-Biotech partner Windward Bio starts Phase 3 POLARIS-1 asthma trial of SKB378/WIN378
  • Sichuan Kelun-Biotech reported positive interim Phase 2 results for asthma antibody SKB378/WIN378 in the POLARIS-1 Phase 2/3 study.
  • The interim readout showed improved lung function with reduced inflammation signals, supporting the program’s move into pivotal testing.
  • Phase 3 has been initiated, testing twice-yearly dosing versus placebo in severe asthma with exacerbation reduction as the main endpoint.
  • Results from the Phase 2 portion have not yet been presented; they are slated for an upcoming medical congress.
  • Windward Bio plans a second Phase 3 asthma trial, POLARIS-2, to start in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260908-12325089), on September 08, 2026, and is solely responsible for the information contained therein.